Assetmark Inc. Sells 10,952 Shares of United Therapeutics Corporation $UTHR

Assetmark Inc. cut its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 634,956 shares of the biotechnology company’s stock after selling 10,952 shares during the period. Assetmark Inc. owned about 1.47% of United Therapeutics worth $309,382,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB grew its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics in the fourth quarter worth about $48,000. Abich Financial Wealth Management LLC bought a new position in shares of United Therapeutics in the third quarter worth about $44,000. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of research analyst reports. Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. UBS Group upped their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $601.50.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $565.87, for a total transaction of $4,696,721.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $25,561,479.64. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $569.28, for a total transaction of $5,408,160.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,063,240.64. The trade was a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 374,270 shares of company stock valued at $193,646,365. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $577.63 on Tuesday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89. The company has a 50-day moving average of $518.73 and a 200 day moving average of $486.05. The firm has a market cap of $25.32 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.19 earnings per share. Sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.